Tuesday, May 24, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Comparison of breakthrough infections in healthcare workers between 3 and 4-dose BNT162b2 vaccine recipients

by Medical Finance
in Coronavirus
Study: Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study. Image Credit: Vincent B David/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The development and mass administration of several coronavirus disease 2019 (COVID-19) vaccines allowed many nations to vaccinate their population. Still, with studies revealing waning immunity and new variants continuing to emerge, the original two-dose vaccination is no longer sufficient. Many governments now advise a third dose, and researchers from the Bnei-Zion Medical Center in Israel have been investigating the use of a fourth dose in healthcare workers.

A preprint version of the study is available on the medRxiv* server, while the article undergoes peer review.

Study: Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study. Image Credit: Vincent B David/Shutterstock
Study: Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study. Image Credit: Vincent B David/Shutterstock

The study

The study cohort included data gathered from healthcare workers (HCWs) in eleven hospitals across Israel. All had received at least three doses of the BNT162b2 vaccine before the beginning of the study, and none had contracted COVID-19 before. Breakthrough infection rates in both triple- and quadruple-vaccinated individuals for comparison. No systematic testing occurred, and all HCWs tested positive took PCR tests of their own volition. Rate ratios for the entire cohort and individual subgroups were calculated, and calculations on 4- and 3-dose recipients who received the dose on the same date were also performed – with matching for subgroups. Time-dependent Cox-regression models allowed the fourth dose administration timing to be accounted for.

There were 29,612 HCWs who were eligible for inclusion in the study, the vast majority of which had received three vaccine doses. 18% had received the fourth dose and were not infected in the first week following administration. Generally, men and older individuals, as well as those directly linked to a medical profession, were more likely to have received a vaccine. The rates of four-dose vaccination were similar across all hospitals, as were HCW characteristics.

Breakthrough infection rates in the four dose groups were 6.9% on average, compared to 19.8% in the three dose group. The rate ratio was 0.35 for basic analysis and 0.61 for matched analysis, with adjusted HR from the Cox-regression model at 0.56, with the effect of the fourth dose consistent over all analyses and over all subgroups. There was no severe disease or death in either group.

Conclusions

The data shows that the fourth dose significantly reduces breakthrough infections in healthcare workers, supporting previous research showing very similar findings in the elderly. The authors highlight that although a fourth dose is less effective than the third dose, it could be worthwhile in occupations such as healthcare workers who suffer from an increased likelihood of infection. They also highlight some weaknesses with the study – as infections may have been missed without routine testing.

While the study concludes with advice for considering a fourth booster for healthcare workers, other scientists have previously argued against this. While more boosters continue to combat the effects of waning immunity and allow developed nations to rebuild quicker, the resultant lack of doses in developing nations can cause greater harm to both groups in the future.

Some of the biggest global and national spikes in COVID-19 cases have been seen when new variants have emerged, with the most obvious cases being the Delta and Omicron variants. As long as the disease has large unvaccinated human reservoirs, new variants that show an even greater ability to evade both natural and vaccine-induced immunity can continue to emerge.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant. Image Credit: Adao/Shutterstock

mRNA booster vaccination found to protect aged mice against the Omicron variant of SARS-CoV-2

by Medical Finance
May 24, 2022
0

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which harbors numerous mutations at the viral spike protein,...

Study: COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase. Image Credit: alessandro guerriero/Shutterstock

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

by Medical Finance
May 24, 2022
0

In a study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from Europe analyzed the alterations...

Study: Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection. Image Credit: Kateryna Kon/Shutterstock

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

by Medical Finance
May 24, 2022
0

In a study published in the latest issue of the journal Cell Reports Medicine, a team of researchers developed a vaccine...

Study: Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection. Image Credit: Corona Borealis Studio/Shutterstock

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

by Medical Finance
May 24, 2022
0

In a new preproof study published in the latest issue of the International Journal of Infectious Diseases, a team of...

Study: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Image Credit: BaLL LunLa/Shutterstock

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

by Medical Finance
May 24, 2022
0

In a recent study posted to the journal Cell, researchers evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination-induced cross-recognition...

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

CDC tells pharmacies to give 4th covid shots to immunocompromised patients

by Medical Finance
May 24, 2022
0

The Centers for Disease Control and Prevention reached out to pharmacists Wednesday to reinforce the message that people with moderate...

Next Post
First patient-derived stem cell model developed for studying oculocutaneous albinism

New training scheme for convolutional neural networks automates cell segmentation and counting

Scientists identify a new switch for controlling motor proteins

Scientists discover how immune proteins defend plants against invading microorganisms

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. Image Credit: peterschreiber.media/ / Shutterstock
    Severe symptoms result in high titers of SARS-CoV-2 antibodies
  • Study: Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. Image Credit: ktsdesign/Shutterstock
    Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply